Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT: 10,586 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
10,586
Total FAERS Reports
367 (3.5%)
Deaths Reported
2,090
Hospitalizations
10,586
As Primary/Secondary Suspect
129
Life-Threatening
101
Disabilities

First Report: 2000 · Latest Report: 20250926

What Are the Most Common ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT Side Effects?

#1 Most Reported
Haemarthrosis
3,360 reports (31.7%)
#2 Most Reported
Haemorrhage
2,925 reports (27.6%)
#3 Most Reported
Fall
709 reports (6.7%)

All ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Haemarthrosis 3,360 31.7% 12 398
Haemorrhage 2,925 27.6% 19 399
Fall 709 6.7% 13 228
Arthralgia 561 5.3% 3 102
Muscle haemorrhage 554 5.2% 1 127
Limb injury 525 5.0% 1 82
Drug ineffective 513 4.9% 8 47
Joint injury 511 4.8% 3 82
Contusion 496 4.7% 5 100
Pain 484 4.6% 4 88
Joint swelling 354 3.3% 2 84
Epistaxis 350 3.3% 3 58
Factor viii inhibition 286 2.7% 5 102
Anti factor viii antibody positive 280 2.7% 6 52
Head injury 275 2.6% 3 74
Haematoma 251 2.4% 3 95
Product dose omission issue 237 2.2% 1 56
Spontaneous haemorrhage 227 2.1% 1 42
Peripheral swelling 223 2.1% 1 60
Extra dose administered 216 2.0% 2 43

Who Reports ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT Side Effects? Age & Gender Data

Gender: 3.0% female, 97.0% male. Average age: 27.3 years. Most reports from: US. View detailed demographics →

Is ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT Getting Safer? Reports by Year

YearReportsDeathsHosp.
2000 3 0 1
2001 5 0 1
2003 2 0 0
2004 3 0 0
2005 4 0 1
2006 3 0 2
2007 7 1 0
2008 11 1 3
2009 10 1 3
2010 12 1 5
2011 14 0 6
2012 27 1 18
2013 87 0 43
2014 214 6 72
2015 399 18 100
2016 330 15 94
2017 313 18 92
2018 301 20 94
2019 631 17 94
2020 1,208 24 209
2021 876 28 177
2022 781 18 161
2023 725 17 165
2024 609 10 125
2025 372 6 87

View full timeline →

What Is ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT Used For?

IndicationReports
Factor viii deficiency 4,268
Product used for unknown indication 2,568
Prophylaxis 1,107
Haemophilia 796
Haemorrhage 751
Haemorrhage prophylaxis 343
Haemostasis 86
Haemarthrosis 67
Immune tolerance induction 53
Acquired haemophilia 50

ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs Alternatives: Which Is Safer?

ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT RESIDUES 743-1636 DELETED ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs ANTIHEMOPHILIC FACTOR, PEGYLATED HUMAN SEQUENCE RECOMBINANT ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs ANTIHEMOPHILIC FACTOR PORCINE, B-DOMAIN TRUNCATED RECOMBINANT ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs APALUTAMIDE ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs APATINIB ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs APIDRA ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs APIDRA SOLOSTAR ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs APIXABAN ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs APLISOL DIAGNOSTIC ANTIGEN ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT vs APOMORPHINE

Official FDA Label for ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT

Official prescribing information from the FDA-approved drug label.